TTP plc

The world of cell and gene therapy is complex and evolving. Can generative AI really help accelerate breakthroughs? While AI's role in drug discovery is well-known, its application in therapy development is only just beginning. According to McKinsey, AI could generate $100 billion for pharma and medical product companies—but how can therapy developers take advantage today? In the latest episode of Invent: Life Sciences, Stuart Lowe is joined by industry leaders: 👥 Kenneth Harris, Chief Strategy Officer & Head of AI, OmniaBio 👥 Sean Bedingfield PhD, PhD, Senior Advisor, Eli Lilly and Company Together, they explore: 🔍 How AI is currently being used in therapy R&D 🔍 Barriers to adoption in such a regulated space 🔍 The future outlook for AI-driven innovations 🎧 Don’t miss this conversation—listen now: https://lnkd.in/egVqbhsW #LifeSciences #AIinPharma #Biotech #Innovation #CellAndGeneTherapy #DigitalHealth

Join Wenshu Xu, Jonathan Wingfield and Greg Walkowiak at the SLAS (Society for Laboratory Automation and Screening) International Conference this week in San Diego, USA. They'll be around to discuss: How bespoke, innovative, and sustainable tools such as high-throughput screening, microfluidics, and organoids can transform drug discovery workflows. Accelerating the Design-Make-Test-Analyse cycle with bespoke lab automation solutions, creating faster, more efficient pathways to clinical trials. Collaborating to develop scalable, sustainable, and future-proof technologies that empower biotech and pharmaceutical innovators to deliver life-changing medicines. Find out more about how we can help you and book a meeting here - https://lnkd.in/e3e_NVu2 #SAS2025

"🚀 AI’s Game-Changing Role in Cell & Gene Therapy Generative AI is revolutionising industries, but how is it transforming cell and gene therapy development? In Episode 4 of the Invent: Life Sciences podcast, host Stuart Lowe is joined by: 🧬 Kenneth Harris, Chief Strategy Officer and Head of AI at OmniaBio 🧬 Sean Bedingfield PhD, PhD, Senior Advisor at Eli Lilly and Company Together, they explore how AI is moving from promise to practice, covering: ✅ The current impact of AI in therapy development ✅ Challenges and opportunities for cell and gene therapy ✅ How AI could unlock $100 billion in economic value, as projected by McKinsey & Company 🎧 Tune in to discover how AI is shaping the future of medicine: https://lnkd.in/gmDNdVaV #AI #Pharma #CellAndGeneTherapy #LifeSciences #HealthcareInnovation #GenerativeAI"

🚨 UTIs: A Global Health Challenge with a Diagnostic Opportunity 🚨 Did you know that urinary tract infections (UTIs) are one of the most common bacterial infections worldwide, affecting over 50% of women at least once in their lifetime? Despite their prevalence, UTI diagnosis often relies on outdated methods, leading to misdiagnosis, overuse of antibiotics, and increasing antimicrobial resistance (AMR). In our latest article, we explore how advancements in UTI diagnostics present a unique opportunity to: 🔬 Enhance diagnostic accuracy – ensuring the right treatment is prescribed, reducing unnecessary antibiotic use. 💊 Improve antimicrobial stewardship – a crucial step in combating rising AMR threats. 👩⚕️ Transform women's health – by addressing the persistent gaps in UTI management and care. With innovation in diagnostic technology, we can empower healthcare providers to make data-driven decisions and provide better patient outcomes. Curious about the future of UTI diagnostics? Read the full article to learn how emerging solutions can make a real impact: 👉 https://lnkd.in/eSVruUJv Let’s start a conversation – how do you see diagnostic innovation shaping the future of UTI treatment? #HealthcareInnovation #AntimicrobialStewardship #WomensHealth #UTIDiagnostics #MedTech #Diagnostics

Accelerating the development of cell and gene therapies – the ‘why’ and the ‘how’" With the cell and gene therapy industry at a pivotal crossroads, one key question looms large: will these groundbreaking therapies become mass-market cures, or will they remain accessible to only a select few? Stuart explored how patient needs can – and should – shape development decisions well before therapies reach the clinic. Therapy developers today must strike a delicate balance between demonstrating short-term clinical progress and preparing for large-scale commercialisation. One powerful solution? Early adoption of process automation. By integrating automation early in development, therapy developers can: ✅ Reduce handling variability ✅ Improve facility utilisation ✅ Accelerate transfer to commercial manufacturing In his talk, Stuart Lowe highlighted how TTP is partnering with companies to implement targeted process automation, using a systematic approach that: 🔹 Focuses on optimising individual process steps 🔹 Identifies the right off-the-shelf or custom hardware 🔹 Aligns scalability with process development goals A huge thank you to everyone who attended and engaged with Stuart’s session. If you’re interested in learning more about how process automation can accelerate your cell and gene therapy development, feel free to reach out! #ATW25 #AdvancedTherapies #CellAndGeneTherapy

Dr. Chris Dawson, head of Biosensing at TTP highlights how Dexcom’s investment in ŌURA reflects a broader trend of CGM manufacturers expanding beyond type 1 diabetes into wellness markets. While additional metrics like heart rate and body temperature are valuable, the real breakthrough lies in reliably turning this data into actionable insights. Read the full article here: https://lnkd.in/eqCN6WNe

Are you attending Pharmapack Europe?If so, come meet our Drug Delivery Team on booth H49! Visit Matthew Parker, Ben Hatton, Fraser McKay and Steve Gowers to find out how we can help you define and develop effective next-generation drug delivery solutions and devices that successfully deliver new formulations and therapies at scale, while increasing patient experience and outcomes. We hope to see you there!

Delivering biologics via inhalation presents unique challenges compared to systemic delivery via injection. It requires precise coordination between device design and formulation to navigate the lung’s barriers, from achieving the ideal droplet size to overcoming natural defence mechanisms and ensuring stability. These complexities mean that every decision, from aerosolisation method to formulation, carries significant downstream impact. In this video, TTP’s Head of Respiratory Device Development, Svilen Savov, and Ben Hatton, Project Lead, discuss the intricacies of delivering biologics via inhalation, including the challenges of aerosolisation, formulation stability, and navigating the lung's natural barriers. 📽️ Watch the full video: https://lnkd.in/eNVU9tU3 #drugdeliverytothelungs #drugdelivery #medicaldevicedevelopment

Join us at Phacilitate Advanced Therapies Week for an unmissable session by Stuart Lowe. 🗓 When: January 22nd, 2025, at 16:00 📍 Where: Advanced Therapies Week 💬Talk Title: "Accelerating the Development of Cell and Gene Therapies – the ‘Why’ and the ‘How’" The cell and gene therapy industry is at a pivotal moment. Will these ground breaking treatments become widely accessible cures, or remain available to a limited few? Can patient needs influence early-stage development decisions to ensure better outcomes? Stuart will tackle these critical questions and more, focusing on how therapy developers can overcome the challenge of balancing short-term clinical progress with long-term scale-up planning. Discover how process automation can: ✅ Reduce handling variability ✅ Improve facility utilisation ✅ Shorten the path to commercial manufacture With real-world insights, Stuart will share how TTP's systematic approach helps therapy developers deploy targeted process automation, including identifying and scaling suitable hardware solutions to meet product development goals. Don’t miss this chance to learn how innovation in automation is transforming the future of cell and gene therapies! #AdvancedTherapies #CellAndGeneTherapy #ProcessAutomation #BiotechInnovation #ATW25 #AdvancedTherapies #CellAndGeneTherapy

Come meet the TTP Neurotech team in Orlando at #NANS2025. Hannah Claridge, Alon Greenenko and Alex Stokoe are excited to present 'Bill', demonstrating how TTP enables efficient implant charging systems with patients + surgeons in mind. We will also exhibiting in-house design and manufacturing capabilities for thin film electrode technologies and look forward to talking about how these and other expertise can accelerate your next neurotechnology product development. Find out more about TTP's work in neurotechnology and book a meeting via the link below, or connect via LinkedIn message. https://lnkd.in/eWPm6TWb #NANS #Neuromodulation #Neurotechnology #AIMD